IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG
IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
IntelGenx Announces Voting Results on Election of Directors
IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical Trial
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
IntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call Transcript
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
IntelGenx Launches Preferred Share Regulation A Offering
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000
IntelGenx Announces Shareholder Approval of Financing Transactions
IntelGenx Receives Approval to Conduct 'MONTPARK' Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease
IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting
IntelGenx Technologies Corp. (IGXT) Q3 2023 Earnings Call Transcript
IntelGenx Reports Third Quarter 2023 Financial Results
IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray
IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow
IntelGenx Provides RIZAFILM® U.S. Commercialization Update
IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Aggregate Gross Proceeds of US$3 Million (Including US$750,000 to be Received by the Company Once Shareholder Approvals Have Been Obtained)
IntelGenx Technologies Corp. (IGXT) Q2 2023 Earnings Call Transcript
IntelGenx Reports Second Quarter 2023 Financial Results
IntelGenx Announces First Agreement for CDMO Packaging Services
IntelGenx to Report Second Quarter 2023 Financial Results on August 14, 2023 – Conference Call to Follow
IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson's Disease
IntelGenx Announces a Change to its Board of Directors
IntelGenx Announces Voting Results on Election of Directors
IntelGenx Technologies Corp. (IGXT) Q1 2023 Earnings Call Transcript
IntelGenx to Report First Quarter 2023 Financial Results on May 11, 2023 – Conference Call to Follow
IntelGenx Technologies Corp. (IGXT) Q4 2022 Earnings Call Transcript
IntelGenx Revises Fourth Quarter and Full Year 2022 Financial Results Reporting and Conference Call Date to March 29, 2023
IntelGenx to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 – Conference Call to Follow
IntelGenx Technologies Corp. (IGXT) Q3 2022 - Earnings Call Transcript
IntelGenx Reschedules Third Quarter 2022 Conference Call Due to Technical Issues Experienced Today by Webcast Vendor
IntelGenx to Report Third Quarter 2022 Financial Results on November 10, 2022 – Conference Call to Follow
IntelGenx Technologies Corp's (IGXT) CEO Horst Zerbe on Q2 2022 Results - Earnings Call Transcript
IntelGenx Technologies' (IGXT) CEO Horst Zerbe on Q1 2022 Results - Earnings Call Transcript
IntelGenx to Report First Quarter 2022 Financial Results on May 12, 2022 – Conference Call to Follow
IntelGenx to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference
IntelGenx Technologies Corp. (IGXT) CEO Horst Zerbe on Q4 2021 Results - Earnings Call Transcript
IntelGenx to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022 – Conference Call to Follow
IntelGenx Technologies Corp. (IGXT) CEO Horst Zerbe on Q3 2021 Results - Earnings Call Transcript
IntelGenx to Report Third Quarter 2021 Financial Results on November 11, 2021 – Conference Call to Follow